{"id":"NCT03086343","sponsor":"AbbVie","briefTitle":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","officialTitle":"A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-09","primaryCompletion":"2019-06-13","completion":"2023-06-06","firstPosted":"2017-03-22","resultsPosted":"2020-06-04","lastUpdate":"2024-07-18"},"enrollment":657,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis (RA)"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":[]},{"type":"DRUG","name":"Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494"]},{"type":"DRUG","name":"Placebo for upadacitinib","otherNames":[]}],"arms":[{"label":"Primary Cohort: Abatacept/Upadacitinib 15 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD","type":"EXPERIMENTAL"},{"label":"30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD","type":"EXPERIMENTAL"},{"label":"30 mg Cohort: Abatacept/Upadacitinib 30 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in biologic disease-modifying antirheumatic drug (bDMARD)-inadequate response or bDMARD-intolerant participants with moderately to severely active RA. The study objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in participants with RA who had completed Period 1.","primaryOutcome":{"measure":"Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority)","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Upadacitinib 15 mg","deltaMin":-2.52,"sd":null},{"arm":"Abatacept","deltaMin":-2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":161,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Czechia","Germany","Greece","Hungary","Ireland","Israel","Italy","Latvia","Mexico","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["33053283","40875187","39031276","37982966","37945286","37308218","36754548","36715850","35751108"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":332},"commonTop":["URINARY TRACT INFECTION","COVID-19","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","RHEUMATOID ARTHRITIS"]}}